Hexarelin Maintains GH-Releasing Power Even After Repeated Dosing in Humans

Repeated hexarelin administration maintained its GH-releasing effect, and combining hexarelin with GHRH produced a synergistic GH response greater than either alone.

Massoud, A F et al.·Clinical endocrinology·1996·Strong EvidenceRCT
RPEP-00370RCTStrong Evidence1996RETHINKTHC RESEARCH DATABASErethinkthc.com/research

Quick Facts

Study Type
RCT
Evidence
Strong Evidence
Sample
Not reported

What This Study Found

Hexarelin maintained GH-releasing efficacy with repeated administration, and hexarelin plus GHRH produced a synergistic GH response exceeding individual effects.

Key Numbers

How They Did This

Randomized, double-blind, crossover RCT with single IV boluses of hexarelin, GHRH, or hexarelin+GHRH administered as two sequential doses to assess responsivity maintenance.

Why This Research Matters

Tolerance is a major concern with repeated peptide use. Demonstrating that hexarelin maintains its effect with repeat dosing supports its viability as a clinical GH secretagogue.

The Bigger Picture

The synergistic effect of hexarelin plus GHRH became a key principle in growth hormone optimization — using two agents working through different receptors produces better results than maximizing either one alone.

What This Study Doesn't Tell Us

Short-term study assessing only acute repeated doses. Long-term tolerance with daily chronic use was not assessed. Sample size and specific participant numbers not detailed in abstract.

Questions This Raises

  • ?Does hexarelin maintain its effectiveness over weeks or months of daily use?
  • ?Is the hexarelin-GHRH synergy consistent across different patient populations and ages?

Trust & Context

Key Stat:
Synergistic combination effect Hexarelin plus GHRH produced a GH response greater than the sum of individual effects, confirming different mechanisms of action
Evidence Grade:
Strong evidence from a randomized, double-blind crossover design. Short-term acute dosing protocol limits conclusions about chronic use tolerance.
Study Age:
Published in 1996, this study established key principles about hexarelin dosing and GHRP-GHRH synergy that inform current peptide protocols.
Original Title:
The effect of repeated administration of hexarelin, a growth hormone releasing peptide, and growth hormone releasing hormone on growth hormone responsivity.
Published In:
Clinical endocrinology, 44(5), 555-62 (1996)
Database ID:
RPEP-00370

Evidence Hierarchy

Meta-Analysis / Systematic Review
Randomized Controlled Trial
Cohort / Case-Control
Cross-Sectional / ObservationalSnapshot without intervening
This study
Case Report / Animal Study
What do these levels mean? →

Frequently Asked Questions

What is hexarelin?

Hexarelin is a synthetic six-amino-acid growth hormone-releasing peptide. It's one of the more potent GHRPs studied and works by stimulating both the pituitary and hypothalamus to release growth hormone.

Why is the synergy with GHRH important?

Hexarelin and GHRH work through completely different receptors and signaling pathways. When combined, they activate two independent GH-release mechanisms simultaneously, producing a much larger GH pulse than either alone — like pressing both the gas pedal and releasing the brake at the same time.

Read More on RethinkPeptides

Cite This Study

RPEP-00370·https://rethinkpeptides.com/research/RPEP-00370

APA

Massoud, A F; Hindmarsh, P C; Matthews, D R; Brook, C G. (1996). The effect of repeated administration of hexarelin, a growth hormone releasing peptide, and growth hormone releasing hormone on growth hormone responsivity.. Clinical endocrinology, 44(5), 555-62.

MLA

Massoud, A F, et al. "The effect of repeated administration of hexarelin, a growth hormone releasing peptide, and growth hormone releasing hormone on growth hormone responsivity.." Clinical endocrinology, 1996.

RethinkPeptides

RethinkPeptides Research Database. "The effect of repeated administration of hexarelin, a growth..." RPEP-00370. Retrieved from https://rethinkpeptides.com/research/massoud-1996-the-effect-of-repeated

Access the Original Study

Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.

This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.